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Summary 
 
Background: Acute Kidney Injury (AKI) is an important adverse outcome after major surgery. 
Perioperative goal directed haemodynamic therapy (GDT) may improve outcomes by reducing 
complications such as AKI.  
  
Objective: To determine if GDT was associated with a reduced incidence of postoperative AKI 
according to specific renal biomarkers.  
  
Design: Prospective sub-study of the OPTIMISE trial, a multi-centre randomised controlled trial 
comparing perioperative GDT to usual patient care (UC).  
  
Setting: Four UK National Health Service hospitals.  
  
Patients: 287 high-risk patients aged ≥50 years undergoing major gastrointestinal surgery. 
  
Outcome measures: The primary outcome measure was AKI defined as urinary neutrophil gelatinase-
associated lipase (NGAL) ≥150ng/ml at either 24 or 72 hours after surgery. Secondary outcomes were 
between-group differences in NGAL measurements and NGAL:creatinine ratios at 24 and 72 hours 
after surgery, AKI of stage 2 or greater according to Kidney Disease Improving Global Outcomes 
(KDIGO) criteria within 30 days of surgery.  
  
Results: In total, 20/287 patients (7%) experienced post-operative AKI of KDIGO grade 2 or 3 within 
30 days. The proportion of patients with urinary NGAL ≥150ng/ml at either 24 or 72h after surgery 
was similar in the two groups (GDT 31/144 [21.5%] patients vs. UC 28/143 [19.6%] patients; p=0.88). 
Absolute values of urinary NGAL were also similar at 24 hours (GDT 53.5 vs. UC 44.1 ng/ml; p=0.38) 
and 72 hours (GDT 45.1 vs. UC 41.1 ng/ml; p=0.50) as were urinary NGAL:creatinine ratios at 24 hours 
(GDT 45 vs. UC 43 ng/mg; p=0.63) and 72 hours (GDT 66 vs. UC 63 ng/mg; p=0.62). The incidence of 
KDIGO defined AKI was also similar between the groups (GDT 9/144 [6%] patients vs UC 11/143 [8%] 
patients; p=0.80). 
  
Conclusion: In this trial, GDT did not reduce the incidence of AKI amongst high-risk 
patients undergoing major gastrointestinal surgery. This may reflect improving standards in usual 
patient care. 
  
Introduction 
While the mortality and morbidity associated with surgery appears to be decreasing (1), the increasing 
volume of surgical procedures in an aging population means that complications following major 
surgery continue to be major health burden (2), particularly in high risk surgical populations (3). 
Investigation of post-operative complications shows the development of perioperative acute kidney 
injury (AKI) (4, 5) has been associated with a greater 30-day mortality, prolonged hospital stay and the 
development of chronic kidney disease (4, 6, 7). The incidence of AKI varies with surgical setting and 
patient population but affects around 13% of patients following major abdominal surgery (4, 5).  
 
Goal Directed Haemodynamic Therapy (GDT) algorithms utilise intravenous fluids and low dose 
inotropic drugs to optimise cardiac output in the high-risk surgical patients(8-10). The findings of 
several randomised trials have suggested this intervention may reduce the number of complications, 
including AKI, in the high-risk patient population (11-14). A meta-analysis of the effects of GDT 
algorithms on post-operative AKI has also suggested a beneficial effect (15). However, the findings of 
the largest trial to date (OPTIMISE) did not indicate any reduction in AKI rates (GDT 17/368 patients 
vs Usual care 17/365 patients) (16).   
 
The introduction of the Kidney Disease Improving Global Outcomes (KDIGO) consensus definition of 
AKI using urine output and changes in serum creatinine has revolutionised the field of AKI research 
(17). Standardised definitions between studies have emphasised the wider consequences of AKI, not 
simply renal replacement therapy.  However, diagnosis of post-operative AKI using serum creatinine 
is complicated by the physiological response to surgery which reduces both urine output and 
creatinine release by skeletal muscle (18, 19). Use of more sensitive biomarkers may improve our 
identification of AKI. Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) is a biomarker of renal 
tubular cell injury that has been used in a number of clinical settings as a more sensitive measure of 
AKI (20-28). In a sub-set of patients recruited to the OPTIMISE trial, we measured urinary NGAL and 
urinary NGAL:creatinine ratio at 24 and 72 hours following major gastrointestinal surgery. We report 
the rates of AKI according to these more sensitive biomarkers and compare them to those defined 
according to the KDIGO criteria (29). 
  
Methods 
The OPTIMISE trial was approved by the East London and City Research Ethics Committee 
(09/H0703/23) and the Medical and Healthcare Products Regulatory Agency (ISRCTN04386758).  
Approval was also given for the collection and storage of blood and urine for further analysis. The trial 
was sponsored by Queen Mary University of London and the urinary biomarker analysis was carried 
out at the University of Dublin. 
 
Data Collection 
The OPTIMISE trial recruited patients over 65 and those patients over 50 with a specified co-morbidity 
undergoing major gastrointestinal surgery lasting more than ninety minutes. Patients were 
randomised into receiving a GDT algorithm or usual care using a computer-generated dynamic 
procedure (minimisation) with a random component. To ensure consistent care across both groups 
certain perioperative parameters were predefined. These were keeping the heart rate between 60-
100 beats per minute, a mean arterial pressure of between 60-100 mmHg, oxygen saturations greater 
than 94% and haemoglobin greater than 80g dl-1. The algorithm used cardiac output monitoring 
(LiDCO) to optimise left ventricular stroke volume and a low dose dopexamine infusion 
(0.5mcg/kg/min) for the duration of surgery and six hours post-operatively. All patients in the 
OPTIMISE trial were followed up during their hospital stay and until 30 days post-operatively. The 
development of any complication was decided by the follow up narrative given to the principal 
investigator or nominated deputy if aware of the allocation. Four of the seventeen sites involved in 
recruiting patients for OPTIMISE recruited into the biomarker sub-study. 
 
Outcome measures 
The primary outcome measure was AKI defined as urinary neutrophil gelatinase-associated lipase 
(NGAL) ≥150ng/ml at either 24 or 72 hours after surgery. Secondary outcomes were between-group 
differences in NGAL measurements and NGAL:creatinine ratios at 24 and 72 hours after surgery , AKI 
of stage 2 or greater according to Kidney Disease Improving Global Outcomes (KDIGO) criteria within 
30 days of surgery i.e. a doubling of serum creatinine relative to pre-operative baseline or reduction 
in urine output (when a catheter was available) up to thirty days after surgery.  
 
  
Sample collection 
Urine samples were collected preoperatively and at 24 and 72 hours after surgery. The urine samples 
were from a sample provided by the patient or withdrawn from an indwelling urinary catheter. These 
were placed into three separate microcentrifuge tubes for each time point and frozen at -80oC. Urine 
samples were stored prior to being sent to a central laboratory for batched analysis. 
 
Measurement of urinary biomarkers 
Urinary NGAL and urinary creatinine were measured in all samples. The Creatinine (CRENZu) 
enzymatic  assay was performed on Abbott Architect ci4100 Clinical Analyser and the NGAL assay was 
performed on Abbott Architect I4100SR Clinical Analyser (30). The two analysers are located in the 
UCD CRC Biomarker Core Lab, SVUH Dublin. Prior to testing instrument calibration was performed, 
followed by imprecision testing (four duplicates of each control per day for 3 days). In addition, 
duplicates of each control were run each day. A total coefficient of variation (CV) of <10% was 
considered acceptable for NGAL, while CV of <3.6% was considered acceptable for CRENZu. NGAL was 
analysed using a two-step immunoassay for the quantitative determination of NGAL in human urine 
using CMIA technology with flexible assay protocols (Chemiflex). Results are presented as NGAL 
concentration and NGAL:Creatinine ratio to standardise for differences in urinary concentration. As 
the validity for standardisation for urinary concentration has been questioned (31), our primary 
analysis was based on absolute urinary NGAL concentration. 
 
Statistical analysis 
Statistical analysis was performed in R v3.3.3 (R Foundation for Statistical Computing, Vienna, Austria) 
using RStudio v1.0.136 (RStudio Inc, Boston, MA, USA).  Continuous data are presented median with 
interquartile range (IQR) and compared with the Wilcoxon rank sum, categorical data were compared 
using Fisher’s exact test.  Predictive accuracy of the biomarker level for AKI outcome was assessed by 
calculation of the receiver operating characteristic area under the curve (ROC-AUC) with 95% 
confidence intervals computed with 2000 stratified bootstrap replicates (32). 
  
Results 
287 of the 734 patients enrolled in the OPTMISE trial were included in this biomarker sub-study 
analysis. Of the 287 patients 144 were in the GDT group and 143 were in the UC group. As in the main 
OPTMISE trial the patients in the UC group were older but there was no other significant difference in 
co-morbidities or in surgical procedure or type (Table 1). 
 
Incidence of AKI  
There was no difference in the incidence of AKI between the GDT and UC groups as measured by 
urinary NGAL (31/144 vs 28/143; p=0.88) and no difference in the urinary NGAL between the groups 
at 24 hours (GDT 53.5 ng/ml vs usual care 44.1 ng/ml; p=0.38) or at 72 hours (GDT 45.1 ng/ml vs usual 
care 41.2 ng/ml; p=0.50) after surgery (Figure 1). Using the NGAL:creatinine ratio demonstrated no 
difference in the incidence of AKI between the two groups at 24 hours (GDT 45ng/mg vs UC 43 ng/mg) 
or 72 hours (GDT 66 ng/mg vs UC 63 ng/mg) after surgery (Figure two). Similarly, there was no 
difference in the rate of AKI as diagnosed by the KDIGO criteria (GDT 9/144 vs usual care 11/143; 
p=0.80) (Table 2).  
 
Relationship between post-operative NGAL and KDIGO defined diagnosis of AKI 
Urinary NGAL was significantly higher in patients who developed AKI at both 24 hours (No AKI 45.7 vs 
AKI 78.0; p=0.01) and at 72 hours after surgery (No AKI 40.1 vs AKI 129.6; p<0.001) (Figure 3, Table 3). 
This was reflected in the urinary NGAL:creatinine ratio which was higher at  24 hours (No AKI 0.43 vs 
AKI 0.82 p=0.015) and 72 hours (No AKI 0.60 vs AKI 4.0; p=0.001) in those who developed AKI (Figure 
4, Table S4). In contrast to post-operative measurement pre-operative urinary NGAL and 
NGAL:Creatinine ratio did not significantly differ between those who did and did not develop AKI 
(Table 3). 
 
  
Discussion 
This sub-study of the OPTIMISE trial did not show any difference in rates of biomarker-defined AKI 
between high-risk surgical patients randomised to receive either a GDT algorithm or usual care. There 
was no difference in urinary NGAL concentrations or urinary NGAL:creatinine ratio at discrete time 
points of 24 or 72 hours after surgery. These results suggest there is no effect of the GDT intervention 
on post-operative AKI either using serum creatinine based definitions or a more sensitive urinary 
biomarkers which capture sub-clinical AKI.  
 
Our findings in this sub-study are in contrast to previous studies of perioperative GDT which have 
demonstrated a reduction in post-operative AKI (11-14, 33, 34) However more recent studies have 
also suggested no AKI reduction from a GDT algorithm in major abdominal surgery(35, 36). 
Improvements in usual care including routine use of haemodynamic targets haemodynamic targets 
and better intra-operative fluid management may explain the loss of effect of GDT in some more 
recent trials.  
 
We are not aware of any larger studies that have used renal biomarkers to assess post-operative AKI 
after GDT in the high risk non-cardiac surgical patient. The importance of post-operative AKI and the 
difficulty in identifying it using a combination of creatinine rise and urine output has increased the 
interest in the ability of a renal specific biomarker to identify post-operative AKI. There are, however, 
some limitations to this analysis. We recruited as many patients as possible into this sub-study, but it 
may be underpowered to detect any difference in the groups, although, no difference in AKI 2-3 was 
shown in the main OPTIMISE study group in line with these findings. Only KDIGO stage 2 and stage 3 
were recorded as a significant renal complication in OPTIMISE and therefore stage 1 AKI was not 
assessed. The incidence of AKI stage 2-3 in OPTIMISE was 5%, however the incidence of urinary 
NGAL≥150ng/ml at 24 or 72h was 13.4% similar to that reported for all AKI in a number of studies in 
major abdominal surgery suggesting our biomarker measurement was capturing the expected 
incidence of AKI in this population (37). Importantly, this sub-study did not aim to assess NGAL as a 
predictive biomarker preceding diagnosis of AKI, in this study AKI-criteria may have been present 
before, at the same time or after biomarker measurement thus we cannot make any conclusions 
regarding utility of NGAL in anticipating AKI.  However, our intention was to use NGAL as a marker of 
renal injury that was mechanistically distinct from a measure of filtration (such as creatinine) that 
would be sensitive for mild, ‘sub-clinical’ AKI to better confirm or refute a renal-protective effect of 
the GDT intervention, not to test the utility of NGAL, which has been examined in many studies. 
There is no universally agreed biomarker-definition of kidney injury and non-specific rises in plasma 
NGAL may occur in inflammatory states. Furthermore, heterogeneity of NGAL as a predictive 
biomarker for AKI in varying clinical settings has led to expressions of doubt of the clinical usefulness 
of NGAL. However, while prediction of AKI in individual patients may be inaccurate, this may be related 
to the inadequacy of creatinine as a gold standard, while analysis of NGAL differences across groups 
of individuals should be more robust. There have been many different cut off values used to determine 
the optimal cut off urinary NGAL in predicting AKI with values been between 20-460 ng/ml(38, 39) 
quoted in literature mostly related to cardiac surgery. This study pre-specified a value of 150ng/ml 
that has been used previously (40), though a more recent review suggests a cut off 80ng/ml may be 
optimal (41).  
 
The time that the samples is a feature of the design of sample collection for OPTIMISE sub-studies. 
Previous studies have measured either urinary or plasma NGAL up to 24 hours after surgery, however 
we measured urinary NGAL at 24 and 72 hours after surgery.  Interestingly 72h urinary NGAL and 
urinary NGAL:creatinine better correlated with post-operative AKI than samples obtained  at 24 hours 
post-operatively. This suggests that in patients with AKI stage 2 or 3 occurring in the post-operative 
period renal tubular injury is still occurring or ongoing three days after surgery, implying that some 
cases of AKI may be associated with post-operative events. Lack of effect of peri- and immediately 
post-operative GDT in preventing AKI is understandable if the majority of renal injury occurring post-
operatively.  In this context, a promising approach for the clinical use of renal biomarkers is to identify 
patients with evolving AKI after major surgery and target an AKI prevention/mitigation strategy at 
these individuals in the post-operative period. Such an approach requires the correct choice of 
biomarker and agreement on appropriate treatments to for patients with early post-operative renal 
injury. Two recent small studies in the context of cardiac and abdominal study have employed this 
approach with the urinary TIMP2xIGFBP7 biomarker of renal tubular cell cycle arrest with favourable 
preliminary results (42, 43).  Thus, in the context of major surgery it may be that renal biomarkers are 
less useful as a read-out of the effect of intervention on renal injury than a method of targeting high-
risk patients to specific interventions that may improve renal outcomes. 
 
Conclusions 
In this biomarker sub-study we did not observe any difference in urinary NGAL concentration, or any 
other biochemical marker of AKI, between the patients having a GDT intervention and those patients 
receiving usual care. This is in keeping with the findings from the overall OPTIMISE trial and may reflect 
high standards of patient care in the control group. Future trials of GDT may measure AKI biomarkers 
to assess the impact of GDT on the incidence of AKI but further research should also focus on the  
predictive ability of kidney injury biomarkers to identify early perioperative kidney injury. 
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Table 1. Baseline Characteristics of Study Population.  
 
Characteristic   GDT Usual care 
  144 143 
 Age (median[IQR]) 70.0 [65.5,75.0] 72  [67.0,77.0] 
 Gender = F (%) 57 (39.9) 49 (34) 
 Urgency = n(%) 7 (4.9) 6 (4.2) 
 Weight (median[IQR]) 72.00 (61.50,83.00) 75.00 (64.75,87.25) 
Risk Factors    
 renal disease (%) 7 (4.9) 4 (2.8) 
 Diabetes Mellitus (%) 20 (14.0) 26 (18.1) 
 Cardiorespiratory Disease 45 (31.5) 51 (35.4 
ASA grade    
 ASA 1 (%) 8 (5.6) 7 (4.9) 
 ASA 2 (%) 85 (59.4) 68 (47.2) 
 ASA 3 (%) 49 (34.3) 67 (46.5) 
 ASA 4 (%) 1 (0.7) 2 (1.4) 
Surgical Procedure   
 Laparoscopic (%) 19 (13.3) 23 (16.0) 
 Open (%) 107 (74.8) 109 (75.7) 
 
Laparoscopic converted to 
open (%) 
17 (11.9) 12 (8.3) 
Procedure type   
 Upper Gastrointestinal (%) 51 (35.7) 55 (38.2) 
 Lower Gastrointestinal (%) 37 (25.9) 40 (27.8) 
 
Small Bowel, Pancreas or 
both (%) 
52 (37.1) 48 (33.3) 
 
Urological or Gynaecological 
surgery involving the gut (%) 
2 (1.4) 1 (0.7) 
 
GDT: goal directed therapy; ASA: American Society of Anesthesiologists 
  
Table 2.  
Postoperative outcomes for study population by treatment group  
 
 
Outcome All patients GDT Usual Care p-value 
Death at 180 days 
(number (%)) 
34/287 
(11.8%) 
15/144 (10.4%) 19/143 (13.3%) 0.569 
Critical Care Free 
Days  
(median [IQR]) 
27.00 
[24.00, 28.00] 
27.00 
[25.00, 28.00] 
26.00 
[23.00, 28.00] 
0.274 
24 and/or 72-hour 
NGAL ≥150 ng/ml  
(number (%)) 
59/292 
(20.2%) 
 
31/144 
(21.5%) 
28/143 
(19.6%) 
0.883 
24-hour NGAL 
 ≥150 ng/ml  
(number (%))  
42/273 
(15.4) 
20/139 
(14.3%) 
22/134 
(16.4%) 
0.74 
72-hour NGAL 
 ≥150 ng/ml  
(number (%)) 
32/236 
(13.6%) 
18/124 
(14.5%) 
14/112 
(12.5%) 
0.71 
Acute Kidney Injury 
stage 2-3 
(number (%)) 
20/287 
(7.0%) 
9/144 
(6.2%) 
11/143 
(7.7%) 
0.804 
Any primary 
complication  
(number (%))  
143/287 
(49.8%) 
59/144 
(41.0%) 
84/143 
(58.7%) 
0.004 
Infective 
complication  
(number (%))  
92/287 
(32.1%) 
35/144 
(24.3%) 
57/143 
(39.9%) 
0.007 
          
GDT: goal directed therapy; NGAL: urinary neutrophil gelatinase-associated lipase 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Postoperative outcomes in patients who developed acute kidney injury 
 
 
Total 
No Acute 
Kidney Injury 
Acute Kidney 
Injury 
p-value 
N 287 267 20  
GENDER = M (%) 180 (62.7) 165 (61.8) 15 (75.0) 0.348 
Age (median [IQR]) 
70.00 [66.00, 
76.00] 
70.00 [66.00, 
76.00] 
69.00 [65.75, 
76.50] 
0.680 
NGAL (median [IQR]) Pre (ng/ml) 12.7 [5.4, 42.5] 
13.3 [5.4, 
41.0] 
8.1 [5.1,70.9] 0.831 
NGAL (median [IQR]) 24h (ng/ml) 48.5 [21.6, 104.6] 
45.6 [20.6, 
92.8] 
78.0 [40.0, 
512] 
0.012 
NGAL (median [IQR]) 72h (ng/ml)  42.4 [21.5, 88.3] 
40.1 [20.2, 
85.8] 
130 [60.3, 
777.4] 
<0.001 
NGAL:Cr (median [IQR]) Pre 
(ng/ml) 
19 [9, 61] 
18.6 [8.7, 
56.3] 
21.3 [9.8, 
145.9] 
0.512 
NGAL:Cr (median [IQR]) 24h 
(ng/ml) 
44 [23, 92] 
43.3 [22.1, 
87.7] 
81.5 [37.5, 
418] 
0.014 
NGAL:Cr (median [IQR]) 72h 
(ng/ml) 
63 [32, 133] 
60.3 [30.1, 
123.1] 
401 [63.1, 
2403.4] 
<0.001 
Critical Care Free days (median 
[IQR]) 
27.00 [24.00, 
28.00] 
27.00 [25.00, 
28.00] 
11.50 [0.00, 
20.50] 
<0.001 
Multi Organ Dysfunction 
Syndrome (%) 
24 (8.4) 10 (3.8) 14 (70.0) <0.001 
Infective Complications (%) 92 (32.1) 79 (29.6) 13 (65.0) 0.002 
Death (%) 34 (11.8) 25 (9.4) 9 (45.0) <0.001 
NGAL:urinary neutrophil gelatinase-associated lipase; NGAL:Cr: urinary neutrophil gelatinase-associated 
lipase creatinine ratio 
 
  
 
Table 4. (supplementary relating to figures one &  two)  
 NGAL and NGAL:Cr results by treatment group allocation 
 
 
 
 
 
 
NGAL:urinary neutrophil gelatinase-associated lipase; NGAL:Cr: urinary neutrophil gelatinase-associated 
lipase creatinine ratio  
 
 
 
 
 
    All GDT Usual care 
p-
value 
Pre-operative 
  
    
  n 269 137 132  
  
NGAL 
(median 
[IQR]) 
12.7 [5.4, 42.5] 12.6 [5.7, 41.9] 
14.6 [5.1, 
42.6] 
0.877 
  
NGAL:Cr  
(median 
[IQR]) 
19 [9, 61] 18 [9, 57] 20 [9, 67] 0.865 
24h       
  n 236 139 134  
  
NGAL 
(median 
[IQR]) 
48.5 [21.6, 104.6] 53.5 [22.4, 118.6] 
44.1 [20.5, 
80.2] 
0.379 
  
NGAL:Cr  
(median 
[IQR]) 
44 [23, 92] 45 [0.23, 0.95] 43 [21, 89] 0.629 
72h       
  n 273 124 112  
  
NGAL 
(median 
[IQR]) 
42.4 [21.5, 88.3] 45.10 [21.7, 94.4] 
41.15 [19.7, 
87.0] 
0.503 
  
NGAL:Cr 
(median 
[IQR]) 
63 [32, 133] 66 [32, 150] 63 [32, 110] 0.620 
Figure one 
 
Urinary NGAL at 3 discrete timepoints comparing GDT group against usual care 
 
 
GDT: goal directed therapy 
Relationship between the presence of a biomarker of acute kidney injury (urinary neutrophil 
gelatinase-associated lipase) and allocation to a goal directed therapy algorithm or usual care for 
perioperative fluid therapy in a high risk surgical population at three time points (before surgery, 24 
hours after surgery and 72 hours after surgery). 
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Figure Two 
Urinary NGAL: creatinine ratio at 3 discrete timepoints comparing GDT group against usual care 
 
GDT: goal directed therapy  
Relationship between the presence of a biomarker of acute kidney injury (urinary neutrophil 
gelatinase-associated lipase) and its ratio to urinary creatinine (urinary neutrophil gelatinase-
associated lipase: creatinine ratio) and allocation to a goal directed therapy algorithm or usual care 
for perioperative fluid therapy in a high risk surgical population at three time points (before surgery, 
24 hours after surgery and 72 hours after surgery). 
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Figure Three 
 
Urinary NGAL at 3 discrete timepoints comparing study population with acute kidney injury with 
no acute kidney injury 
 
 
 
No AKI: no acute kidney injury; AKI: acute kidney injury 
Relationship between the presence of a biomarker of acute kidney injury (urinary neutrophil 
gelatinase-associated lipase) and the diagnosis of acute kidney injury by Kidney Disease: Improving 
Global Outcomes (KDIGO) stage two and three in a high risk surgical population at three time points 
(before surgery, 24 hours after surgery and 72 hours after surgery). 
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Figure Four 
 
Urinary NGAL: creatinine ratio at 3 discrete timepoints comparing study population with acute 
kidney injury with no acute kidney injury 
 
 
 
No AKI: no acute kidney injury; AKI: acute kidney injury 
Relationship between the presence of a biomarker of acute kidney injury (urinary neutrophil 
gelatinase-associated lipase) and its ratio to urinary creatinine (urinary neutrophil gelatinase-
associated lipase: creatinine ratio) and the diagnosis of acute kidney injury by Kidney Disease: 
Improving Global Outcomes (KDIGO) stage two and three in a high risk surgical population at three 
time points (before surgery, 24 hours after surgery and 72 hours after surgery). 
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